Gina Rinehart, executive chairwoman of Hancock Prospecting, is investing in Lumitron’s high-resolution X-ray imaging technology to detect ore contaminants and cancer [1].
This partnership bridges industrial mining and medical diagnostics, potentially transforming how raw materials are processed and how early-stage diseases are identified. The move signals a strategic expansion for Rinehart into the deep-tech sector beyond traditional resource extraction.
The investment is reported across various figures, with Sky News stating the amount is $72 million [1]. Other reports cite a deal of $70 million [3] or U.S. $50 million [2]. A press release dated June 25, 2026, clarified that Hancock Prospecting provided an initial U.S. $50 million investment into Lumitron [5].
Under the terms of the agreement, the company retains the right to increase its investment to U.S. $100 million during 2026 [5]. Lumitron Technologies, based in California, specializes in imaging that can identify impurities in iron ore [2].
Beyond mining applications, the technology is being touted for its medical potential. Rita Panahi of Sky News said the "revolutionary imaging technology can detect contaminants in iron ore but also cancer" [1]. The collaboration aims to commercialize these imaging capabilities for both ore inspection and cancer therapy, or diagnostics [4].
The investment was first reported on June 18, 2026 [2]. While some industry reports focus primarily on the high-resolution imaging for ore, the promotional materials from the partnership emphasize the dual-use nature of the X-ray platform [1], [4].
Hancock Prospecting is now positioned to influence the development of a world-first imaging technology that serves two vastly different industries—heavy mining and clinical medicine [4].
“The revolutionary imaging technology can detect contaminants in iron ore but also cancer.”
This investment demonstrates a trend of resource magnates diversifying into dual-use technologies that apply industrial-grade sensing to healthcare. By funding Lumitron, Rinehart is betting that the same precision required to find contaminants in iron ore can be pivoted toward medical diagnostics, potentially creating a new revenue stream in the biotechnology market while optimizing mining efficiency.
